ADMET & DMPK X(Y) (20xx) pp-pp; doi: 10


doi: 10.5599/admet.1.3.8 45 

ADMET & DMPK 1(3) (2013) 45; doi: 10.5599/admet.1.3.8 

 
Open Access : ISSN : 1848-7718  

http://www.pub.iapchem.org/ojs/index.php/admet/index   

Editorial Board Member: brief biography 

Hong Wan 
 

 

Dr. Hong Wan is currently Executive Director and Head of DMPK/Tox of Shanghai Hengrui 

Pharmaceutical CO LTD (SHHRP). Prior to joining SHHRP in May 2013, he was Executive Director of DMPK & 

Bioanalysis Department at a CRO in China, Crown Bioscience Inc (Taicang), for 3 years. Before moving back 

to China in 2010, he worked for AstraZeneca RD, Mölndal, Sweden for 10 years, from Discovery DMPK & 

Bioanalytical Chemistry to Lead Generation DMPK and Physical Chemistry, and as a Principal Scientist since 

2007. While in this role, he contributed to a number of drug hunting projects as well as led in developing 

high-throughput DMPK & physicochemical assays. He received his PhD from the Department of Analytical 

Chemistry, Stockholm University in 1996, and was Associate Professor in the Department of Chemistry, 

Karlstad University in 2001. He completed his BS degree in 1984 and his MS degree in 1987 in the Analytical 

Chemistry Department of Lanzhou University and the Lanzhou Institute of Chemical Physics, Chinese 

Academia of Science, respectively. Dr. Wan has authored and co-authored over 50 publications in 

peer-reviewed journals and has received invitations to peer review. He is also an Editorial Board member 

for Expert Opinion on Drug Metabolism and Toxicology, The Open Spectroscopy Journal, and 

ADMET/DMPK. 

 

©2013 by the authors; licensee IAPC, Zagreb, Croatia. This article is an open-access article distributed under the terms and 
conditions of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/3.0/)  

 

http://www.pub.iapchem.org/ojs/index.php/admet/index
http://creativecommons.org/licenses/by/3.0/